Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Karolinska Development, also known as KDventures, is based in Solna, Sweden, and focuses on investing in Nordic life science companies. The firm was founded to support the development of treatments for serious diseases and has a team experienced in research, development, financing, and commercialization of pharmaceutical and medtech projects.
This firm invests in pharmaceutical and medtech companies, particularly those in phase 2 clinical trials or early commercialization phases. Typical investments occur at pre-seed, seed, and Series A stages, with a strategy that emphasizes partnerships with leading specialist investors in the life sciences sector.
Notable companies in Karolinska Development's portfolio include Forendo Pharma, acquired by Organon for USD 945 million in 2021; BioArctic, which targets Alzheimer’s and Parkinson’s diseases and was listed on NASDAQ Stockholm in 2017; and Xspray, which achieved a successful exit in 2015 with improved and generic pharmaceuticals.
Submit your pitch through their website's contact form or reach out via email with your deck for consideration.
Yes, Karolinska Development often leads investment rounds, particularly in early-stage companies within their focus sectors.
The firm is open to follow-on investments, especially for companies that demonstrate significant progress in their development phases.
Specific details about the fund size are not disclosed, but the firm actively invests in early-stage life science companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.